Junaid Arshad
NPI: 1831506898
Total Payments
$18,699
2024 Payments
$13,592
Companies
39
Transactions
189
Medicare Patients
302
Medicare Billing
$64,376
Payment Breakdown by Category
Consulting$8,075 (43.2%)
Other$5,462 (29.2%)
Food & Beverage$3,772 (20.2%)
Travel$995.45 (5.3%)
Education$393.94 (2.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $8,075 | 2 | 43.2% |
| Honoraria | $5,462 | 2 | 29.2% |
| Food and Beverage | $3,772 | 176 | 20.2% |
| Travel and Lodging | $995.45 | 5 | 5.3% |
| Education | $393.94 | 4 | 2.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Exelixis Inc. | $6,920 | 18 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $6,768 | 17 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,795 | 14 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $472.79 | 23 | $0 (2021) |
| Amgen Inc. | $346.35 | 9 | $0 (2021) |
| Astellas Pharma US Inc | $245.68 | 8 | $0 (2022) |
| Celgene Corporation | $211.64 | 10 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $162.13 | 9 | $0 (2023) |
| Eisai Inc. | $146.09 | 8 | $0 (2021) |
| TerSera Therapeutics LLC | $130.53 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,592 | 19 | Exelixis Inc. ($6,864) |
| 2023 | $144.11 | 3 | Foundation Medicine, Inc. ($98.03) |
| 2022 | $1,612 | 3 | Novartis Pharmaceuticals Corporation ($1,575) |
| 2021 | $1,323 | 72 | Merck Sharp & Dohme Corporation ($106.09) |
| 2020 | $650.95 | 29 | Amgen Inc. ($173.56) |
| 2019 | $277.90 | 10 | Celgene Corporation ($136.55) |
| 2018 | $681.96 | 27 | Merck Sharp & Dohme Corporation ($164.06) |
| 2017 | $416.60 | 26 | NOVARTIS PHARMACEUTICALS CORPORATION ($157.02) |
All Payment Transactions
189 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Exelixis Inc. | CABOMETYX (Drug) | Honoraria | Cash or cash equivalent | $2,825.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/06/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | Cash or cash equivalent | $163.48 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/06/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | Cash or cash equivalent | $49.82 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/23/2024 | TerSera Therapeutics LLC | Xermelo (Drug) | Food and Beverage | In-kind items and services | $130.53 | General |
| Category: Oncology | ||||||
| 08/14/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $6,500.00 | General |
| 07/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $81.96 | General |
| 06/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $174.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 04/03/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $15.56 | General |
| Category: ONCOLOGY | ||||||
| 03/07/2024 | Exelixis Inc. | CABOMETYX (Drug) | Honoraria | Cash or cash equivalent | $2,637.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 03/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $419.25 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 03/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $299.79 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 03/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | Cash or cash equivalent | $97.58 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 03/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $70.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 03/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | Cash or cash equivalent | $55.15 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 03/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $8.28 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 03/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | Cash or cash equivalent | $4.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 02/29/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | Cash or cash equivalent | $42.93 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 02/29/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $15.06 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 02/29/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $3.09 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/25/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $21.21 | General |
| Category: ONCOLOGY | ||||||
| 05/23/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $24.87 | General |
| Category: Oncology | ||||||
| 02/06/2023 | Foundation Medicine, Inc. | FOUNDATIONONE LIQUID CDX | Food and Beverage | In-kind items and services | $98.03 | General |
| 12/22/2022 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Consulting Fee | Cash or cash equivalent | $1,575.00 | General |
| Category: ONCOLOGY | ||||||
| 04/20/2022 | Astellas Pharma US Inc | PADCEV (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Oncology | ||||||
| 03/01/2022 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | Cash or cash equivalent | $18.98 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 204 | 426 | $92,651 | $40,973 |
| 2022 | 2 | 81 | 174 | $43,386 | $21,067 |
| 2020 | 1 | 17 | 18 | $6,390 | $2,335 |
Total Patients
302
Total Services
618
Medicare Billing
$64,376
Procedure Codes
8
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 76 | 277 | $62,036 | $30,526 | 49.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 51 | 51 | $18,732 | $6,769 | 36.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 18 | 20 | $5,320 | $1,861 | 35.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 46 | 64 | $5,093 | $1,484 | 29.1% |
| G0316 | Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | Facility | 2023 | 13 | 14 | $1,470 | $333.21 | 22.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 50 | 143 | $32,071 | $16,555 | 51.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 31 | 31 | $11,315 | $4,512 | 39.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 17 | 18 | $6,390 | $2,335 | 36.5% |
About Junaid Arshad
Junaid Arshad is a Student in an Organized Health Care Education/Training Program healthcare provider based in Lakewood, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/22/2014. The National Provider Identifier (NPI) number assigned to this provider is 1831506898.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Junaid Arshad has received a total of $18,699 in payments from pharmaceutical and medical device companies, with $13,592 received in 2024. These payments were reported across 189 transactions from 39 companies. The most common payment nature is "Consulting Fee" ($8,075).
As a Medicare-enrolled provider, Arshad has provided services to 302 Medicare beneficiaries, totaling 618 services with total Medicare billing of $64,376. Data is available for 3 years (2020–2023), covering 8 distinct procedure/service records.
Ad
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Hematology & Oncology
- Location Lakewood, CA
- Active Since 07/22/2014
- Last Updated 05/28/2020
- Taxonomy Code 390200000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1831506898
Products in Payments
- CABOMETYX (Drug) $6,886
- LUTATHERA (Drug) $1,621
- KEYTRUDA (Biological) $413.70
- OPDIVO (Biological) $223.38
- Revlimid (Drug) $160.07
- Lenvima (Drug) $146.09
- ZEJULA (Drug) $143.64
- Xermelo (Drug) $130.53
- MONJUVI (Drug) $119.10
- Stivarga (Drug) $77.87
- KISQALI (Drug) $68.19
- VENCLEXTA (Drug) $63.23
- PADCEV (Drug) $60.02
- Neulasta (Biological) $52.42
- TASIGNA (Drug) $50.49
- XPOVIO (Drug) $49.96
- XOSPATA (Drug) $48.37
- ELIQUIS (Drug) $44.20
- Nplate (Biological) $42.96
- ZEPZELCA (Drug) $39.07
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Lakewood
Dr. Michael Fischman, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $4,830
Student in an Organized Health Care Education/Training Program $4,830
Michelle Paturzo, Pa-C, PA-C
Student in an Organized Health Care Education/Training Program — Payments: $4,471
Student in an Organized Health Care Education/Training Program $4,471
Dr. Elizabeth Carewe, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $1,807
Student in an Organized Health Care Education/Training Program $1,807
Catherine Cunningham, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $1,672
Student in an Organized Health Care Education/Training Program $1,672
Peter Mcguire, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $1,600
Student in an Organized Health Care Education/Training Program $1,600
Bikram Sekhon
Student in an Organized Health Care Education/Training Program — Payments: $1,124
Student in an Organized Health Care Education/Training Program $1,124